What Causes Polycystic Kidney Disease: Gene Mutations

Polycystic kidney disease (PKD) traces back to inherited mutations in a small handful of genes that control how kidney cells grow, divide, and maintain their structure. The two most common culprits are PKD1 and PKD2, which together account for the vast majority of autosomal dominant PKD, the form that affects roughly one in every 400 to 1,000 people worldwide. A rarer childhood form stems from mutations in a different gene entirely. But calling PKD a single-gene disease undersells its complexity: the specific gene involved, the type of mutation, background genetics, and even factors outside the DNA sequence itself all shape when and how severely the disease strikes.

The Two Major Genes Behind Dominant PKD

Autosomal dominant polycystic kidney disease (ADPKD) is by far the more common form, and it results from a mutation in either PKD1 or PKD2.¹ PKD1, located on chromosome 16, accounts for the larger share of cases. In a large Taiwanese cohort where disease-causing mutations were identified in over 600 families, PKD1 mutations made up about half of all cases and PKD2 roughly 29%.² The remaining families carried mutations in rarer genes or had variants that couldn’t be definitively classified.

PKD1 and PKD2 encode two related proteins called polycystin-1 and polycystin-2. These proteins work together at the surface of kidney cells, particularly on tiny hair-like projections called primary cilia. When either protein is defective, the cell loses its ability to properly sense its environment and regulate its own growth. That loss of control is ultimately what leads to fluid-filled cysts ballooning out of the kidney tissue over years and decades.

Why Which Gene Matters for Severity

One of the most practically important distinctions in PKD genetics is whether someone carries a PKD1 or PKD2 mutation. PKD1 mutations tend to produce a more aggressive disease course, with kidney failure arriving earlier and symptoms accumulating faster. A landmark comparison found that the median age at which people with PKD1 reached end-stage kidney disease or death was about 53 years, compared with roughly 69 years for those with PKD2.³ People with PKD2 mutations were also less likely to develop high blood pressure, blood in the urine, or urinary tract infections.

That said, PKD2 is far from harmless. The same study showed that people with PKD2 still had significantly shorter life expectancy than the general population. And analyses of cardiac complications have confirmed that PKD1 is linked to a higher risk of progressive kidney failure and more severe symptoms overall compared to PKD2.⁴ Knowing which gene carries the mutation can help doctors and patients plan ahead, particularly around when to begin monitoring kidney function more aggressively and when to consider treatment options.

The Recessive Form and a Different Gene

Autosomal recessive polycystic kidney disease (ARPKD) is a separate condition, rarer and typically far more severe. It is caused by mutations in the PKHD1 gene on chromosome 6, which is one of the largest human genes, spanning at least 86 exons.⁵ PKHD1 encodes a protein called fibrocystin, which, like the polycystins, localizes to primary cilia and plays a role in how cells within the kidney and bile ducts develop and maintain their shape.

Because ARPKD requires two defective copies of PKHD1 (one inherited from each parent), both parents are typically carriers who show no symptoms themselves. The disease often presents in infancy or even before birth, detected on prenatal ultrasound as massively enlarged kidneys. Many affected children develop significant kidney impairment early in life, and liver involvement, particularly congenital hepatic fibrosis, is a hallmark of the disease.⁶ While patients with ARPKD have been prospectively evaluated using imaging and measures of kidney function in conjunction with confirmed PKHD1 mutations, the clinical picture varies widely even among people carrying similar mutations.⁷

How Cysts Actually Form

Inheriting a mutated PKD gene does not mean every kidney cell immediately starts forming cysts. The prevailing explanation involves what researchers call a “two-hit” model, borrowed from cancer biology. You’re born with one working copy and one defective copy of the relevant gene in every cell. Cysts begin forming only when individual kidney cells lose that remaining good copy through a second, random mutation picked up over time. Once both copies are knocked out in a single cell, that cell gains a growth advantage and proliferates into a cyst.⁸

This model explains a few things that would otherwise be puzzling. It accounts for why cysts appear in scattered, seemingly random locations across the kidneys rather than uniformly. It also explains why ADPKD is progressive: over a lifetime, more and more cells accumulate that second hit, so cyst burden increases with age. And it helps explain why some people with identical inherited mutations can have very different disease courses, since the timing and location of those second hits are essentially random.

At the cellular level, the loss of functional polycystins disrupts signaling within the primary cilium. Calcium and a signaling molecule called cAMP become dysregulated, which causes kidney lining cells to proliferate abnormally and secrete fluid into the developing cysts.⁹ Both structural and functional defects in primary cilia have been shown to drive not just cyst growth but also vascular hypertension, a frequent companion of PKD.¹⁰

When There Is No Family History

A common assumption is that if you have PKD, someone else in your family must have it too. That is usually true, but not always. Studies have shown that brand-new (de novo) mutations do occur. In one analysis of over 200 ADPKD patients, about 15% had de novo disease, meaning their mutations arose spontaneously and were not found in either biological parent.¹¹ That same study uncovered a few cases of germline and somatic mosaicism, where a parent carried the mutation in only some of their cells, making it invisible on standard testing but still transmissible to children.

Earlier work had also definitively confirmed de novo pathogenic mutations in ADPKD patients where established parentage ruled out any inherited origin.¹² The practical upshot: a negative family history does not rule out PKD. If imaging shows characteristic cysts and other features fit, genetic testing is worth pursuing regardless of what your parents’ medical records say.

Rarer Genes That Cause PKD-Like Disease

While PKD1 and PKD2 dominate the ADPKD landscape, genetic testing has revealed that mutations in several other genes can produce overlapping kidney cyst conditions. In the Taiwanese cohort mentioned earlier, small numbers of families carried pathogenic variants in PKHD1 (yes, the same gene behind ARPKD, but acting differently in certain contexts), GANAB, and ALG8.²

Two other genes deserve mention for how they blur the lines between PKD and other kidney diseases. Mutations in DNAJB11 produce a condition that looks partly like ADPKD and partly like a group of diseases characterized by scarring between the kidney’s tubules. In affected families, kidneys develop cysts but typically do not enlarge the way they do in classic ADPKD. Instead, the kidneys may actually shrink over time due to progressive scarring, and kidney failure tends to arrive later in life.¹³ Similarly, mutations in ALG5 cause a picture of non-enlarged cystic kidneys with few or no liver cysts and kidney failure that tends to develop between the 60s and 90s.¹⁴

These atypical genes collectively account for a small fraction of PKD cases, but identifying them matters. A patient with DNAJB11 or ALG5 disease may be misdiagnosed as having classic ADPKD and given inaccurate expectations about disease trajectory. Genetic testing can catch these distinctions.

Why People With the Same Mutation Can Have Very Different Outcomes

Even within a single family sharing the exact same PKD1 mutation, the severity of disease can vary enormously. One sibling might need a transplant in their 40s while another keeps reasonable kidney function into their 60s. Research has shown that modifier genes in the broader genetic background are a significant driver of this variability. Studies of families with extreme differences in disease progression among members found patterns consistent with one or a few modifier genes exerting a major influence on how PKD1 manifests.¹⁵

Beyond modifier genes, the specific type of mutation matters. PKD1 mutations that completely eliminate the protein (truncating mutations) are generally associated with worse outcomes than those that produce a partially functional protein (missense mutations). And large phenotypic variability among affected individuals has been attributed to both genic and allelic differences, along with possible modifier gene effects.¹⁶ Environmental factors, sex, and epigenetic changes layer additional complexity on top of the purely genetic picture.

Epigenetic and Inflammatory Factors That Accelerate Cyst Growth

The mutations themselves are necessary but not sufficient to explain the full trajectory of PKD. Epigenetic regulators, which control how genes are read without changing the DNA sequence, have been linked to cyst progression. Inflammatory markers can be detected even before cyst growth becomes clinically apparent, and the infiltration of immune cells like macrophages has been associated with cyst expansion and worsening kidney function in both human patients and animal models.¹⁷

Oxidative stress also feeds into the disease process. In mouse models of ADPKD, removing a key antioxidant defense pathway increased the production of harmful reactive oxygen species and promoted cyst growth. Conversely, activating that same pathway pharmacologically slowed cyst formation and disease progression by remodeling how certain genes were expressed in PKD cells.¹⁸ These findings suggest that while the mutation lights the fuse, inflammation and oxidative damage help feed the fire, and they represent potential targets for treatment alongside the mutations themselves.

Effects Beyond the Kidneys

PKD gene mutations don’t just affect the kidneys. The proteins encoded by PKD1, PKD2, and PKHD1 are expressed in tissues throughout the body, and this explains why PKD often involves other organs. Liver cysts are the most common extrarenal feature of ADPKD, appearing in the majority of patients by middle age, though they rarely cause liver failure. In ARPKD, liver involvement takes the form of congenital hepatic fibrosis, driven by the same PKHD1 mutations that cause the kidney disease. Fibrocystic liver diseases as a group are classified among the ciliopathies because they stem from dysfunctions of proteins expressed in the primary cilia of bile duct cells.¹⁹

A more dangerous extrarenal complication is the increased risk of brain aneurysms. Compared with the general population, people with ADPKD are more likely to develop saccular intracranial aneurysms, which can rupture and cause life-threatening bleeding. The strongest risk factor for aneurysm is a family history of brain aneurysms or rupture, with high blood pressure and smoking adding further risk.²⁰ This is why some PKD patients, particularly those with a family history of aneurysms, are offered periodic brain imaging as a screening measure.

Animal Models and the Cilia Connection

Much of what we know about how PKD mutations lead to cysts comes from animal research. A particularly informative mouse model is the cpk mouse, which develops polycystic kidneys due to disruption of a protein called cystin. When researchers expressed cystin in kidney cells grown in the lab, it localized to the primary cilia, overlapping with another PKD-related protein called polaris.²¹ This was one of the findings that cemented the idea that the single cilium on each kidney cell is central to PKD, and that ciliary dysfunction, not just a defect in one specific protein, is the common thread tying various forms of cystic kidney disease together.

The cilia connection has also helped researchers understand why so many different gene mutations can produce superficially similar diseases. Whether the affected protein is polycystin-1, polycystin-2, fibrocystin, cystin, or one of the rarer players, the downstream result converges on defective ciliary signaling. This convergence has focused drug development efforts on the shared pathways rather than on each individual gene.

Current Treatment and Emerging Gene Therapies

For decades, PKD management was limited to controlling blood pressure, managing pain, and eventually transplant or dialysis. The first disease-modifying drug, tolvaptan, works by blocking the vasopressin V2 receptor in kidney cells, which reduces the cAMP levels that drive fluid secretion into cysts. Studies have confirmed that tolvaptan slows cyst growth and may also reduce inflammation-related kidney injury.²² It remains the only approved therapy specifically targeting ADPKD’s molecular pathway, and it comes with significant side effects, particularly excessive thirst and urination, along with a risk of liver injury that requires monitoring.

The gene therapy landscape for PKD is still early-stage but increasingly active. Several approaches are in development, including antisense molecules that silence disease-promoting small RNAs, viral vectors that deliver corrective genetic material, and direct gene editing. Among the most promising are strategies aimed at boosting the expression of the patient’s remaining functional PKD1 copy. One recent proof-of-concept study used a CRISPR-based activation system to crank up the production of polycystin-1 from the endogenous PKD1 gene. In cell models, this approach increased polycystin-1 protein levels and significantly reduced both cell proliferation and cyst formation.²³

Other research groups have used base editing in human stem-cell-derived kidney organoids to model and correct PKD mutations, defining a “polycystin threshold” below which cysts form and above which they can be prevented. The idea that restoring just enough polycystin function, without needing to fully repair the gene, could be sufficient to suppress disease represents a shift in how researchers think about treatment goals.²⁴ Alongside these, broader gene therapy strategies including antisense oligonucleotides and CRISPR-based tools have shown potential in animal models and early clinical trials.²⁵ None of these genetic interventions are ready for routine clinical use, but the pace of progress has been striking. For a disease that had no targeted treatment at all until 2018, the pipeline looks genuinely different than it did a decade ago.